GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
(4) - EconoTimes)
Add as a preferred source on Google
DUBLIN, Ireland, April 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Apr. 1, 2018 of inducement restricted stock units for an aggregate of 55,395 ordinary shares to 21 new employees.
Some of the restricted stock units vest over four years, with 1/4 of the shares vesting on each anniversary of the applicable vesting commencement date, and some of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
